There is one clinical trial.
This is a phase 3 clinical trial, randomized, single-center, opened, controlled, to evaluate efficacy and safety of early administration of colchicines in patients older than 70 years, with high risk of pulmonary complications due to coronavirus SARS-CoV2 (COVID-19). An approximately number of 1000 subjects meeting all inclusion and none exclusion criteria will be randomized either to receive colchicines or symptomatic treatment with paracetamol during 21 days.
Description: not delayed more than 48 hours from initial symptoms
Measure: A confirmed diagnosis from COVID-19 infection (by positive PCR test) will be mandatory . Time: 48 hours